COMPOSITION PHARMACEUTIQUE CONTENANT, COMME PRINCIPE ACTIF, UNE PROTÉINE DE FUSION DANS LAQUELLE UN PEPTIDE PÉNÉTRANT LES TUMEURS ET UN AGENT ANTIANGIOGENÈSE SONT FUSIONNÉS, POUR LA PRÉVENTION ET LE TRAITEMENT DU CANCER OU DE MALADIES ASSOCIÉES À L'ANGIOGENÈSE
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
